表紙
市場調查報告書
商品編碼
1037295

吸入麻醉的全球市場 (2021-2026年):產業趨勢、市場佔有率、市場規模、成長預測、成長機會

Inhalation Anesthesia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

出版日期: | 出版商: IMARC Services Private Limited | 英文 144 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球吸入麻醉的市場規模從2015年到2020年顯示緩慢的成長,在預測期間內預計以約5%的年複合成長率成長。

需要外科治療的慢性疾病增加是促進該市場成長的重要要素之一。再加上容易罹患心血管疾病,神經疾病,呼吸疾病,退化性疾病等疾病的老年人增加,也推動市場成長。此外,麻醉回收系統的開發等各種技術的進步,也成為促進成長的要素。

本報告提供全球吸入麻醉的市場調查,市場概要,市場規模的變化、預測,產品、用途、終端用戶、地區/主要國家等各種區分的明細,競爭環境,主要企業簡介等彙整資訊。

目錄

第1章 序文

第2章 調查範圍、調查手法

第3章 摘要整理

第4章 簡介

第5章 全球吸入麻醉市場

  • 市場概要
  • 市場業績
  • COVID-19的影響

第6章 市場明細:各產品

  • DESFLURANE
  • SEVOFLURANE
  • Isoflurane
  • 其他

第7章 市場明細:各用途

  • 引進
  • 維持

第8章 市場明細:各終端用戶

  • 醫院
  • 門診病人手術中心
  • 其他

第9章 市場明細:各地區

  • 北美
  • 亞太地區
  • 歐洲
  • 南美
  • 中東、非洲

第10章 SWOT分析

第11章 價值鏈分析

第12章 波特五力分析

第13章 價格分析

第14章 競爭情形

  • 市場結構
  • 主要企業
  • 主要企業的簡介
    • Abbvie Inc.
    • Baxter International Inc.
    • Fresenius SE & Co. KGaA
    • Halocarbon Products Corporation
    • Hikma Pharmaceuticals PLC
    • Lunan Pharmaceutical Group Co. Ltd
    • Merck KGaA
    • Piramal Enterprises Ltd.
    • Troikaa Pharmaceuticals Ltd
目錄
Product Code: SR1020G316_Report

The global inhalation anesthesia market exhibited moderate growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of around 5% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end-use sectors. These insights are included in the report as a major market contributor.

Inhalation anesthesia refers to the anesthetic medications that are induced for maintaining the levels of general anesthesia and sedation in the body during surgery. Some of the commonly used inhalation anesthetics include nitrous oxide, desflurane, isoflurane and sevoflurane. These anesthetics are administered using a laryngeal face airway and a tracheal tube connected to a vaporizer. They are highly effective in small doses and can induce respiratory depression, reduce the arterial blood pressure and increase cerebral blood flow when used in unmoderated quantities. In comparison to the traditionally used intravenous variants, inhalation anesthesia does not accumulate in the body and aids in preventing excessive dosage, while promoting normal functioning of the patient.

Inhalation Anesthesia Market Trends:

  • The increasing prevalence of chronic medical disorders requiring surgical treatments is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is more susceptible to ailments, such as cardiovascular, neurological, respiratory and degenerative disorders, is providing a thrust to the market growth. Hospitals and other ambulatory healthcare centers are widely using sevoflurane and other ether-based inhalation anesthetic agents with low pungency and non-irritant odor for patients with asthma or sensitive air passages. Additionally, various technological advancements, such as the development of anesthesia recycling systems for extracting anesthetic compounds from hospital vents and operating rooms, are acting as other growth-inducing factors. In line with this, anesthesia manufacturers are also producing variants with enhanced compatibility and minimal side-effects to cater to the requirements of patients sensitive to anesthetic agents. Other factors, including significant improvements in the healthcare infrastructure, especially in the developing economies, along with extensive research and development (R&D) activities, are anticipated to drive the market toward growth.

Key Market Segmentation:

  • IMARC Group provides an analysis of the key trends in each sub-segment of the global inhalation anesthesia market, along with forecasts at the global, regional and country level from 2021-2026. Our report has categorized the market based on region, product, application and end user.

Breakup by Product:

  • Desflurane
  • Sevoflurane
  • Isoflurane
  • Others

Breakup by Application:

  • Induction
  • Maintenance

Breakup by End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbvie Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Halocarbon Products Corporation, Hikma Pharmaceuticals PLC, Lunan Pharmaceutical Group Co. Ltd, Merck KGaA, Piramal Enterprises Ltd. and Troikaa Pharmaceuticals Ltd. Key Questions Answered in This Report:

  • How has the global inhalation anesthesia market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global inhalation anesthesia market?
  • What are the key regional markets?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the application?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global inhalation anesthesia market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Inhalation Anesthesia Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Desflurane
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Sevoflurane
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Isoflurane
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Application

  • 7.1 Induction
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Maintenance
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ambulatory Surgical Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbvie Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Baxter International Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Fresenius SE & Co. KGaA
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Halocarbon Products Corporation
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Hikma Pharmaceuticals PLC
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Lunan Pharmaceutical Group Co. Ltd
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Merck KGaA
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Piramal Enterprises Ltd.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
    • 14.3.9 Troikaa Pharmaceuticals Ltd
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio